The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 519-527

  Serra, Raffaele ^a   Gallelli, Luca ^a   Conti, Angela ^a   De Caridi, Giovanni ^b   Massara, Mafalda ^b   Spinelli, Francesco ^b   Buffone, Gianluca ^a   Caliò, Francesco Giuseppe ^c   Amato, Bruno ^d   Ceglia, Simona ^a   Spaziano, Giuseppe ^e   Scaramuzzino, Luca ^f   Ferrarese, Alessia Giovanna ^g   Grande, Raffaele ^a   de Franciscis, Stefano ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

Author keywords

Arterial ulcer; Metalloproteinases; Mixed ulcer; Neutrophil gelatinase associated lipocalin

Indexed keywords

MATRIX METALLOPROTEINASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SULODEXIDE; ACUTE PHASE PROTEIN; GLYCOSAMINOGLYCAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMPRESSION THERAPY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MIXED ULCER; OPEN STUDY; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN SURGERY; SKIN ULCER; SUBFASCIAL ENDOSCOPIC PERFORATING SURGERY; SUPERFICIAL VENOUS OPEN SURGERY; TREATMENT DURATION; VEIN INSUFFICIENCY; WESTERN BLOTTING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VARICOSE ULCER; VERY ELDERLY; WOUND HEALING;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; LIPOCALINS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; QUALITY OF LIFE; VARICOSE ULCER; WOUND HEALING;

EID: 84900822786     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S61770     Document Type: Article

References (62)

1. Patton LR. Are community leg ulcer clinics more cost-effective than home care visits? J Wound Care. 2009;18(2):49-50, 52.
2. Hampton S. An introduction to various types of leg ulcers and their management. Br J Nurs. 2006;15(11):S9-S13.
3. Forssgren A, Fransson I, Nelzén O. Leg ulcer point prevalence can be decreased by broad-scale intervention: a follow-up cross-sectional study of a defined geographical population. Acta Derm Venereol. 2008;88(3):252-256.
4. Andersson E, Hansson C, Swanbeck G. Leg and foot ulcer prevalence and investigation of the peripheral arterial and venous circulation in a randomised elderly population. An epidemiological survey and clinical investigation. Acta Derm Venereol. 1993;73(1):57-61.
5. Apelqvist JA, Lepäntalo MJ. The ulcerated leg: when to revascularize. Diabetes Metab Res Rev. 2012;28 Suppl 1:30-35.
6. Serra R, Buffone G, de Franciscis A, etal. A genetic study of chronic venous insufficiency. Ann Vasc Surg. 2012;26(5):636-642.
7. Serra R, Grande R, Buffone G, Costanzo G, Damiano R, de Franciscis S. Chronic venous disease is more aggressive in patients with varicocele. Acta Phlebologica. 2013;14:57-60.
8. Serra R, Buffone G, Costanzo G, etal. Varicocele in younger as risk factor for inguinal hernia and for chronic venous disease in older: preliminary results of a prospective cohort study. Ann Vasc Surg. 2013;27(3):329-331.
9. Georgopoulos S, Kouvelos GN, Koutsoumpelis A, etal. The effect of revascularization procedures on healing of mixed arterial and venous leg ulcers. Int Angiol. 2013;32(4):368-374.
10. Lantis JC 2nd, Boone D, Lee L, Mendes D, Benvenisty A, Todd G. The effect of percutaneous intervention on wound healing in patients with mixed arterial venous disease. Ann Vasc Surg. 2011;25(1):79-86.
11. Ghauri AS, Nyamekye I, Grabs AJ, Farndon JR, Poskitt KR. The diagnosis and management of mixed arterial/venous leg ulcers in community-based clinics. Eur J Vasc Endovasc Surg. 1998;16(4):350-355.
12. Nag F, De A, Hazra A, Chatterjee G, Ghosh A, Surana TV. Chronic venous ulceration of leg associated with peripheral arterial disease: an underappreciated entity in developing country. Int Wound J. Epub November 22, 2012.
13. Humphreys ML, Stewart AH, Gohel MS, Taylor M, Whyman MR, Poskitt KR. Management of mixed arterial and venous leg ulcers. Br J Surg. 2007;94(9):1104-1107.
14. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3): 562-573.
15. Serra R, Buffone G, Molinari V, etal. Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. Int Wound J. Epub March 21, 2013.
16. de Franciscis S, De Sarro G, Longo P, etal. Hyperhomocysteinaemia and chronic venous ulcers. Int Wound J. Epub February 19, 2013.
17. Serra R, Buffone G, de Franciscis A, etal. Skin grafting followed by low-molecular-weight heparin long-term therapy in chronic venous leg ulcers. Ann Vasc Surg. 2012;26(2):190-197.
18. de Franciscis S, Grande R, Buffone G, Serra R. Chronic venous ulceration of the lower limbs and thrombosis. Acta Phlebologica. In press.
19. Gasbarro V, Amato B, Izzo M, etal. Quercetin and chronic venous ulceration of the lower limbs. Acta Phlebologica. 2013;14:61-65.
20. Serra R, Buffone G, Falcone D, etal. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen. 2013;21(3):395-401.
21. Serra R, Grande R, Buffone G, Gallelli L, de Franciscis S. The effects of minocycline on extracellular matrix in patients with chronic venous leg ulcers. Acta Phlebologica. 2013;14(3):99-107.
22. Amato B, Coretti G, Compagna R, etal. Role of matrix metalloproteinases in non-healing ulcers. Int Wound J. Epub October 24, 2013.
23. de Franciscis S, Mastroroberto P, Gallelli L, Buffone G, Montemurro R, Serra R. Increased plasma levels of metalloproteinase-9 and neutrophil gelatinase-associated lipocalin in a rare case of multiple artery aneurysm. Ann Vasc Surg. 2013;27(8):1185. e5-e7.
24. de Franciscis S, Gallelli L, Battaglia L, etal. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease. Int Wound J. Epub May 15, 2013.
25. Busceti MT, Grande R, Amato B, etal. Pulmonary embolism, metalloproteinases and neutrophil gelatinase associated lipocalin. Acta Phlebologica. 2013;14(3):115-121.
26. Serra R, Buffone G, Costanzo G, etal. Altered metalloproteinase-9 expression as least common denominator between varicocele, inguinal hernia, and chronic venous disorders. Ann Vasc Surg. 2014;28(3): 705-709.
27. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696-1701.
28. Voigt J, Driver VR. Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical wounds, and chronic wounds: a systematic review and meta-analysis of randomized controlled trials. Wound Repair Regen. 2012;20(3):317-331.
29. Humbert P, Mikosinki J, Benchikhi H, Allaert FA. Efficacy and safety of a gauze pad containing hyaluronic acid in treatment of leg ulcers of venous or mixed origin: a double-blind, randomised, controlled trial. Int Wound J. 2013;10(2):159-166.
30. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012;12(2):73-81.
31. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006;24(3-4):214-226.
32. Mannello F, Medda V, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11(3):354-365.
33. Yung S, Chau MK, Zhang Q, Zhang CZ, Chan TM. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501.
34. Lewis EJ, Lewis JB, Greene T, etal; Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58(5):729-736.
35. Eklöf B, Rutherford RB, Bergan JJ, etal; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248-1252.
36. Fragomeni G, Merola A, Serra R, de Franciscis S, Amato F. A nonlinear lumped parameters model to analyze the dynamics of venous reflux. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:1407-1410.
37. de Franciscis S, Gasbarro V, Amato B, Buffone G, Grande R, Serra R. Hemodynamic surgery versus conventional surgery in chronic venous disease: a multicenter retrospective study. Acta Phlebologica. 2013;14(3):109-114.
38. Al-Qaisi M, Nott DM, King DH, Kaddoura S. Ankle brachial pressure index (ABPI): An update for practitioners. Vasc Health Risk Manag. 2009;5:833-841.
39. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337-343.
40. Obradovic M, Lal A, Liedgens H. Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain. Health Qual Life Outcomes. 2013;11:110.
41. Pina E, Furtado K, Franks PJ, Moffatt CJ. [Leg ulcers in Portugal: an underestimated health care problem]. Rev Port Cir Cardiotorac Vasc. 2004;11(4):217-221. Portuguese.
42. Finlayson K, Edwards H, Courtney M. Relationships between preventive activities, psychosocial factors and recurrence of venous leg ulcers: a prospective study. J Adv Nurs. 2011;67(10):2180-2190.
43. Moffatt CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross F. Prevalence of leg ulceration in a London population. QJM. 2004;97(7): 431-437.
44. Baker SR, Stacey MC, Singh G, Hoskin SE, Thompson PJ. Aetiology of chronic leg ulcers. Eur J Vasc Surg. 1992;6(3):245-251.
45. Nelzén O, Fransson I. True long-term healing and recurrence of venous leg ulcers following SEPS combined with superficial venous surgery: a prospective study. Eur J Vasc Endovasc Surg. 2007;34(5): 605-612.
46. Fletcher A, Cullum N, Sheldon TA. A systematic review of compression treatment for venous leg ulcers. BMJ. 1997;315(7108):576-580.
47. Dean S. Leg ulcers-causes and management. Aust Fam Physician. 2006;35(7):480-484.
48. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, De Sarro G. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014;25(2):131-137.
49. Kucukguven A, Khalil RA. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets. 2013;14(3):287-324.
50. Raffetto JD. Inflammation in chronic venous ulcers. Phlebology. 2013;28 Suppl 1:61-67.
51. Serra R, Gallelli L, Buffone G, etal. Doxycycline speeds up healing of chronic venous ulcers. Int Wound J. Epub April 5, 2013.
52. Trengove NJ, Stacey MC, MacAuley S, etal. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999;7(6):442-452.
53. Serra R, Grande R, Butrico L, etal. Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration. Int Wound J. Epub February 25, 2014.
54. Serra R, Grande R, Gallelli L, Rende P, Scarcello E, Buffone G, et al. Carotid body paragangliomas and Matrix Metalloproteinases. Ann Vasc Surg. Epub April 2, 2014.
55. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V; Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) Group. Randomised, double blind, multicentre, placebo controlled study of Sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002;87(6):947-952.
56. Condorelli M, Chiariello M, Dagianti A, etal. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994;23(1):27-34.
57. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998;18(1):1-20.
58. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs. 1995;49(6):856-884.
59. Redini F, Tixier JM, Petitou M, Choay J, Robert L, Hornebeck W. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J. 1988;252(2):515-519.
60. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003;109(5-6):333-339.
61. Cirujeda JL, Granado PC. A study on the safety, efficacy, and efficiency of Sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006;57(1):53-64.
62. Ciszewicz M, Polubinska A, Antoniewicz A, Suminska-Jasinska K, Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009;153(3):118-123.